Alzheimer’s Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research

Dementia and cancer are becoming increasingly common in Western countries. In the last two decades, research has focused on Alzheimer’s disease (AD) and cancers, particularly, breast cancer (BC) and prostate cancer (PC), has been substantially funded both in Europe and worldwide.

While the results of scientific research have contributed to improving our understanding of disease etiopathology, still the prevalence of chronic degenerative conditions are still very high in the whole world. By definition, there is the perfect model. In particular, the animal model of AD, BC, and the PC has been and still is traditionally used in basic research / fundamental, translational and preclinical to study human disease mechanisms, identifying new therapeutic targets and develop new drugs

However, inadequate animal models of several important features of the human disease; Therefore, they often can not pave the way for the development of effective drugs in human patients. The emergence of new tools and models of technology in the life sciences, and the growing need for a multidisciplinary approach has prompted many interdisciplinary research initiatives. With substantial funds invested in biomedical research, it is becoming necessary to define and implement indicators to monitor contributions to innovation and impact of funded research.

Here, we discuss some of the issues underlying the failure of translation in AD, BC, and research PCs, and illustrates how the indicators can be applied to the output size and the impact of the retrospective funded biomedical research.
Disease coronavirus 19 (COVID-19) has dramatically changed daily life, including the field of research of the disease (AD) Alzheimer’s. This perspective article discusses some of the ways in which COVID-19 has impacted the field, anticipating some long-lasting effects, and explore strategies to address the needs of current and future. Areas of impact include the integrity of the study, regulatory issues and industry, and the involvement of the participants.

The proposed strategy to address these challenges include the analytical method to handle large degree lost data and development, user-friendly, means of data collection and remote patient-centered assessments. We also highlight the importance of maintaining the welfare of participants as a first priority and constant.

 Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research
Alzheimer’s Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research

Synaptosome as a tool in the study of Alzheimer’s disease

synaptic dysfunction is an integral feature of the disease (AD) pathophysiology of Alzheimer’s. In fact, the prodromal manifestations of structural and functional deficits in synaptic much before the appearance of overt disease indicates that pathological hallmarks of AD may be regarded as a degenerative disorder of synapses.

Some research instruments and techniques have allowed us to study synaptic function and plasticity and their changes in pathological conditions, such as AD. One such tool is the biochemical preparation isolated from apart and resealed synaptic terminal, the “synaptosomes”. Due to the preservation of many physiological processes such as metabolism and enzymatic activity, synaptosomes has proven to be an ex vivo model of system is needed for the study of synaptic physiology either when isolated from fresh or cryopreserved tissue, and from animal or human post-mortem tissue.

Total RNA - Alzheimer's Disease: Occipital Lobe

R1236062Alz-10 10 ug
EUR 460

Total RNA - Alzheimer's Disease: Corpus Callosum

R1236045Alz-10 10 ug
EUR 460

Total RNA - Alzheimer's Disease: Precentral Gyrus

R1236073Alz-10 10 ug
EUR 460

Total RNA - Alzheimer's Disease: Postcentral Gyrus

R1236072Alz-10 10 ug
EUR 460

Pons (Alzheimer's Disease) Lysate

XBL-10298 0.1 mg
EUR 796.2
Description: Human pons tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human pons tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the pons tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The pons tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

cDNA - Alzheimer's Disease: Brain: Pons

C1236071Alz 40 reactions
EUR 802

Total Protein - Alzheimer's Disease: Brain

P1236035Alz 1 mg
EUR 542

Frozen Tissue Section - Alzheimer's Disease: Brain: Pons

T1236071Alz 5 slides
EUR 523

Total Protein - Alzheimer's Disease: Brain: Amygdala

P1236036Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Thalamus

P1236079Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Cerebellum

P1236039Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Hippocampus

P1236052Alz 1 mg
EUR 667

Total Protein - Alzheimer's Disease: Brain: Frontal Lobe

P1236051Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Parietal Lobe

P1236066Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Temporal Lobe

P1236078Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Occipital Lobe

P1236062Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Corpus Callosum

P1236045Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Precentral Gyrus

P1236073Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Medulla oblongata

P1236057Alz 1 mg
EUR 542

Total Protein - Alzheimer's Disease: Brain: Postcentral Gyrus

P1236072Alz 1 mg
EUR 542

Genomic DNA - Alzheimer's Disease: Brain: Pons, from a single donor

D1236071Alz 50 ug
EUR 562

cDNA - Alzheimer's Disease: Brain

C1236035Alz 40 reactions
EUR 802

Paraffin Tissue Section - Alzheimers Disease: Brain: Pons

T2236071Alz 5 slides
EUR 262

Amygdala (Alzheimer's Disease) Lysate

XBL-10274 0.1 mg
EUR 796.2
Description: Human amygdala tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human amygdala tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the amygdala tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The amygdala tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Thalamus (Alzheimer's Disease) Lysate

XBL-10310 0.1 mg
EUR 796.2
Description: Human thalamus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human thalamus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the thalamus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The thalamus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Hippocampus (Alzheimer's Disease) Lysate

XBL-10286 0.1 mg
EUR 922.2
Description: Human hippocamps tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human hippocamps tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the hippocamps tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The hippocamps tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

cDNA - Alzheimer's Disease: Brain: Amygdala

C1236036Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Thalamus

C1236079Alz 40 reactions
EUR 802

Frontal Lobe (Alzheimer's Disease) Lysate

XBL-10282 0.1 mg
EUR 796.2
Description: Human frontal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human frontal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the frontal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The frontal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Human Alzheimer's Disease Primer Library

HAZD-I 1 set
EUR 657.6

Parietal Lobe (Alzheimer's Disease) Lysate

XBL-10294 0.1 mg
EUR 796.2
Description: Human parietal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human parietal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the parietal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The parietal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Temporal Lobe (Alzheimer's Disease) Lysate

XBL-10314 0.1 mg
EUR 796.2
Description: Human temporal lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human temporal lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the temporal lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The temporal lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

cDNA - Alzheimer's Disease: Brain: Cerebellum

C1236039Alz 40 reactions
EUR 802

Occipital lobe (Alzheimer's Disease) Lysate

XBL-10290 0.1 mg
EUR 796.2
Description: Human occipital lobe tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human occipital lobe tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the occipital lobe tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The occipital lobe tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Human iPS Cell Line (Alzheimer's Disease)

CSC-00850L One Frozen vial Ask for price

cDNA - Alzheimer's Disease: Brain: Hippocampus

C1236052Alz 40 reactions
EUR 975

Corpus Callosum (Alzheimer's Disease) Lysate

XBL-10278 0.1 mg
EUR 796.2
Description: Human corpus Callosum tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human corpus Callosum tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the corpus Callosum tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The corpus Callosum tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Precentral Gyrus (Alzheimer's Disease) Lysate

XBL-10306 0.1 mg
EUR 796.2
Description: Human precentral gyrus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human precentral gyrus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the precentral gyrus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The precentral gyrus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

Amygdala (Alzheimer's Disease) Membrane Lysate

XBL-10272 0.1 mg
EUR 752.1
Description: Human brain amygdala tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human amygdala tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain amygdala tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain amygdala tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Postcentral Gyrus (Alzheimer's Disease) Lysate

XBL-10302 0.1 mg
EUR 796.2
Description: Human postcentral gyrus tissue lysate was prepared by homogenization using a proprietary technique. The tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The human postcentral gyrus tissue total protein is provided in a buffer including HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the postcentral gyrus tissue pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The postcentral gyrus tissue is then Western analyzed by either GAPDH or β-actin antibody, and the expression level is consistent with each lot.

cDNA - Alzheimer's Disease: Brain: Frontal Lobe

C1236051Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Parietal Lobe

C1236066Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Temporal Lobe

C1236078Alz 40 reactions
EUR 802

Hippocampus (Alzheimer's Disease) Membrane Lysate

XBL-10284 0.1 mg
EUR 852.9
Description: Human brain hippocamps tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human hippocamps tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain hippocamps tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain hippocamps tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

cDNA - Alzheimer's Disease: Brain: Occipital Lobe

C1236062Alz 40 reactions
EUR 802

cDNA - Alzheimer's Disease: Brain: Precentral Gyrus

C1236073Alz 40 reactions
EUR 802

Frozen Tissue Section - Alzheimer's Disease: Brain

T1236035Alz 5 slides
EUR 523

Hippocampus (Alzheimer's Disease) Cytoplasmic Lysate

XBL-10283 0.1 mg
EUR 273.3
Description: Human brain hippocamps tissue cytoplasmic protein lysate was prepared by isolating the cytoplasmic protein from whole tissue homogenates using a proprietary technique. The human hippocamps tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The cytoplasmic protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, glycerol, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain hippocamps tissue cytoplasmic protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain hippocamps tissue cytoplasmic protein is then Western analyzed by GAPDH antibody, and the expression level is consistent with each lot.

cDNA - Alzheimer's Disease: Brain: Postcentral Gyrus

C1236072Alz 40 reactions
EUR 802

Temporal Lobe (Alzheimer's Disease) Membrane Lysate

XBL-10312 0.1 mg
EUR 752.1
Description: Human brain temporal lobe tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human temporal lobe tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated brain temporal lobe tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated brain temporal lobe tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

Non-Ab Component of Alzheimer's Disease Amyloid

5-01639 4 x 1mg Ask for price

Non-Ab Component of Alzheimer's Disease Amyloid

SP-89317-1 1 mg
EUR 343.2

Frozen Tissue Section - Alzheimer's Disease: Brain: Amygdala

T1236036Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Thalamus

T1236079Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Pituitary

T1236068Alz 5 slides
EUR 971

Frozen Tissue Section - Alzheimer's Disease: Brain: Cerebellum

T1236039Alz 5 slides
EUR 523

Non-Ab Component of Alzheimer's Disease Amyloid Peptide

abx266991-1ml 1 ml
EUR 925

Non-Ab Component of Alzheimer's Disease Amyloid Peptide

abx266991-200l 200 µl
EUR 375

Frozen Tissue Section - Alzheimer's Disease: Brain: Hippocampus

T1236052Alz 5 slides
EUR 971

Paraffin Tissue Section - Alzheimer's Disease: Brain: Cerebellum

T2236039Alz 5 slides
EUR 262

Genomic DNA - Alzheimer's Disease: Brain, from a single donor

D1236035Alz 50 ug
EUR 562

Frozen Tissue Section - Alzheimer's Disease: Brain: Frontal Lobe

T1236051Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Parietal Lobe

T1236066Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Temporal Lobe

T1236078Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Occipital Lobe

T1236062Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Corpus Callosum

T1236045Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Precentral Gyrus

T1236073Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Medulla oblongata

T1236057Alz 5 slides
EUR 523

Frozen Tissue Section - Alzheimer's Disease: Brain: Postcentral Gyrus

T1236072Alz 5 slides
EUR 523

Paraffin Tissue Section - Alzheimer's Disease: Brain: Medulla oblongata

T2236057Alz 5 slides
EUR 523

HighQC™ Human IPSC From Fibroblast-Familial Alzheimer's Disease

ABC-SC2075 1 vial Ask for price
Description: Cell Type: iPSC; Primary Tissue: Fibroblast; Reprogramming Method: Episomal Plasmid; Disease: Familial Alzheimer's Disease; Cells are only guaranteed with purchase of Gentaur Media and Gentaur Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Genomic DNA - Alzheimer's Disease: Brain: Thalamus, from a single donor

D1236079Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Cerebellum, from a single donor

D1236039Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Frontal Lobe, from a single donor

D1236051Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Parietal Lobe, from a single donor

D1236066Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Temporal Lobe, from a single donor

D1236078Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Occipital Lobe, from a single donor

D1236062Alz 50 ug
EUR 562

Amyloid-beta Protein (12-28) / Alzheimer's Disease beta-Protein / SP-17 (Human)

018-04 200 μg
EUR 50.76

Genomic DNA - Alzheimer's Disease: Brain: Corpus Callosum, from a single donor

D1236045Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Precentral Gyrus , from a single donor

D1236073Alz 50 ug
EUR 562

Amyloid-beta Protein (1-28) / Alzheimer's Disease beta-Protein / SP-28 (Human)

018-02 200 μg
EUR 108

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue I, 7 different tissues

T6236444Alz 5 slides
EUR 1249

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue II, 7 different tissues

T6236445Alz 5 slides
EUR 1249

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue III, 8 different tissues

T6236446Alz 5 slides
EUR 1249

Frozen Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue IV, 7 different tissues

T6236564Alz 5 slides
EUR 1249

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue I, 8 different tissues

T8236444Alz 5 slides
EUR 713

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue II, 7 different tissues

T8236445Alz 5 slides
EUR 713

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue IV, 7 different tissues

T8236564Alz 5 slides
EUR 713

Genomic DNA - Alzheimer's Disease: Brain: Medulla oblongata, from a single donor

D1236057Alz 50 ug
EUR 562

Genomic DNA - Alzheimer's Disease: Brain: Postcentral Gyrus , from a single donor

D1236072Alz 50 ug
EUR 562

Paraffin Tissue Section Panel - Human Disease Tissue, Alzheimer's Disease, Multi-tissue III, 8 different tissues

T8236446Alz 5 slides
EUR 713

Membrane Protein - Alzheimer's Disease:Brain: Amygdala

P3236036Alz 0.1 mg
EUR 472

Membrane Protein - Alzheimer's Disease:Brain: Hippocampus

P3236052Alz 0.1 mg
EUR 584

Membrane Protein - Alzheimer's Disease:Brain: Temporal Lobe

P3236078Alz 0.1 mg
EUR 472

Total Protein - Parkinson's Disease: Brain: Pons

P1236071Par 1 mg
EUR 542

Paraffin Tissue Section - Alzheimers Disease: Brain

T2236035Alz 5 slides
EUR 262

Alzheimers Disease gamma-Secretase Detection Set

PSI-1820 1 Set
EUR 752.1
Description: Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The β-amyloid protein precursor (APP) is cleaved by three enzymes (TACE, BACE/BACE2 and γ-secretase) at three distinct sites (α, β and γ respectively). The γ-secretase complex is a membrane-bound aspartyl protease that can cleave certain proteins at peptide bonds buried within the hydrophobic environment of the lipid bilayer and is composed of the proteins APH1, nicastrin, PEN2 and presenilin1. Its cleavage of APP results in either the non-toxic p3 (from the α and γ cleavage site) or the toxic Aβ (from the β and γ cleavage site). APH1 was initially identified as a component of the Notch pathway and exists in at least three distinct isoforms with APH1a as the principal isoform present in the γ-secretase complex. Mice deficient in this isoform, but not the other two, were lethal at E10.5, with impaired vascular and neural development observed. Besides acting as a critical component of the γ-secretase complex, nicastrin is also thought to be involved in cell proliferation and signaling, especially in regards to activation of Notch receptors as loss of nicastrin expression results in mouse embryonic lethality. Presenilin1 was initially identified a marker of susceptibility to early-onset Alzheimer’s disease.;;For images please see PDF data sheet

Alzheimers Disease B-Amyloid Protein Detection Set

PSI-1812 1 Set
EUR 752.1
Description: Accumulation of the amyloid-β peptide (Aβ) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. The βamyloid protein precursor (APP) is cleaved by one of two βsecretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for βsecretase to generate the 4 kDa amyloid-β peptide (Aβ), which is deposited in the Alzheimer’s disease patients’ brains. BACE was identified by several groups independently and designated β-site APP cleaving enzyme (BACE) . BACE is a transmembrane aspartic protease and co-localizes with APP. BACE2 also cleaves APP at β-site and at a different site within Aβ. BACE2 locates on chromosome 21q22.3, the so-called ‘Down critical region’, suggesting that BACE2 and Aβ may also contribute to the pathogenesis of Down syndrome.;;For images please see PDF data sheet

Paraffin Tissue Section - Alzheimers Disease: Brain: Amygdala

T2236036Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Thalamus

T2236079Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Frontal Lobe

T2236051Alz 5 slides
EUR 262

Total Protein - Multiple Sclerosis Disease: Brain: Pons

P1236071Msc 1 mg
EUR 542

Paraffin Tissue Section - Alzheimers Disease: Brain: Hippocampus

T2236052Alz 5 slides
EUR 834

Paraffin Tissue Section - Alzheimers Disease: Brain: Parietal Lobe

T2236066Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Temporal Lobe

T2236078Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Corpus Callosum

T2236045Alz 5 slides
EUR 262

Paraffin Tissue Section - Alzheimers Disease: Brain: Occipital Lobe

T2236062Alz 5 slides
EUR 262

PSEN2 (untagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1

SC119867 10 µg Ask for price

PSEN2 (untagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2

SC324404 10 µg Ask for price

PSEN2 (untagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2

SC109639 10 µg Ask for price

PSEN2 (GFP-tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2

RG202921 10 µg Ask for price

PSEN2 (GFP-tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1

RG223613 10 µg Ask for price

PSEN2 (Myc-DDK-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1

RC223613 10 µg Ask for price

PSEN2 (Myc-DDK-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2

RC202921 10 µg Ask for price

Paraffin Tissue Section - Alzheimers Disease: Brain: Precentral Gyrus (Movement)

T2236073Alz 5 slides
EUR 262

Lenti ORF clone of Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mGFP tagged

RC202921L2 10 µg Ask for price

Lenti ORF clone of Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, mGFP tagged

RC202921L4 10 µg Ask for price

Paraffin Tissue Section - Alzheimers Disease: Brain: Postcentral Gyrus (Sensation)

T2236072Alz 5 slides
EUR 262

Lenti-ORF clone of PSEN2 (mGFP-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1

RC223613L4 10 µg Ask for price

3`UTR clone of presenilin 2 (Alzheimer disease 4) (PSEN2) transcript variant 1 for miRNA target validation

SC207101 10 µg Ask for price

3`UTR clone of presenilin 2 (Alzheimer disease 4) (PSEN2) transcript variant 2 for miRNA target validation

SC207102 10 µg Ask for price

Lenti ORF clone of Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, Myc-DDK-tagged

RC202921L1 10 µg Ask for price

Lenti ORF clone of Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, Myc-DDK-tagged

RC202921L3 10 µg Ask for price

Lenti-ORF clone of PSEN2 (Myc-DDK-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1

RC223613L3 10 µg Ask for price

Lenti ORF particles, PSEN2 (mGFP-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1, 200ul, >10^7 TU/mL

RC223613L4V 200 µl Ask for price

Lenti ORF particles, PSEN2 (mGFP-tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, 200ul, >10^7 TU/mL

RC202921L2V 200 µl Ask for price

Lenti ORF particles, PSEN2 (mGFP-tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, 200ul, >10^7 TU/mL

RC202921L4V 200 µl Ask for price

Lenti ORF particles, PSEN2 (Myc-DDK tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, 200ul, >10^7 TU/mL

RC202921L1V 200 µl Ask for price

Lenti ORF particles, PSEN2 (Myc-DDK tagged) - Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 2, 200ul, >10^7 TU/mL

RC202921L3V 200 µl Ask for price

Lenti ORF particles, PSEN2 (Myc-DDK-tagged)-Human presenilin 2 (Alzheimer disease 4) (PSEN2), transcript variant 1, 200ul, >10^7 TU/mL

RC223613L3V 200 µl Ask for price

Total RNA - Diabetic Disease: Colon

R1236090Dia-50 50 ug
EUR 460

Total RNA - Diabetic Disease: Stomach

R1236248Dia-50 50 ug
EUR 460

Total RNA - Diabetic Disease: Pancreas

R1236188Dia-50 50 ug
EUR 460

Total RNA - Diabetic Disease: Esophagus

R1236106Dia-50 50 ug
EUR 460

Total RNA - Congenital heart disease: Heart

R1236122Hd-3 50 ug
EUR 460

Rat Pons Total RNA

RR-207 0.025mg
EUR 160

Single Donor Human Alzheimer's Serum

ISERSALZ each
EUR 209
Description: Single Donor Human Alzheimer's Serum

Single Donor Human Alzheimer's Plasma

IPLASALZ each
EUR 209
Description: Single Donor Human Alzheimer's Plasma

Rat-WS Pons Total RNA

RR-207-WS 0.025mg
EUR 160

Mouse CD1 Pons Total RNA

MR-207 0.025mg
EUR 160

Mouse C57 Pons Total RNA

MR-207-C57 0.025mg
EUR 180

Mouse Balbc Pons Total RNA

MR-207-BLC 0.025mg
EUR 180

Total Protein - Parkinson's Disease: Brain

P1236035Par 1 mg
EUR 542

Frozen Tissue Section - Parkinson's Disease: Brain: Pons

T1236071Par 5 slides
EUR 523

Paraffin Tissue Section - Parkinson's Disease: Brain: Pons

T2236071Par 5 slides
EUR 262

Total RNA - Human Adult Normal Tissue: Brain: Pons

R1234071-10 10 ug
EUR 221

Total Protein - Congenital heart disease: Heart

P1236122Hd-3 1 mg
EUR 542

Total Protein - Multiple Sclerosis Disease: Brain

P1236035Msc 1 mg
EUR 542

Total Protein - Parkinson's Disease: Brain: Amygdala

P1236036Par 1 mg
EUR 542

Total Protein - Parkinson's Disease: Brain: Thalamus

P1236079Par 1 mg
EUR 542

Total Protein - Parkinson's Disease: Brain: Cerebellum

P1236039Par 1 mg
EUR 542

Frozen Tissue Section - Multiple Sclerosis Disease: Brain: Pons

T1236071Msc 5 slides
EUR 523

Paraffin Tissue Section - Multiple Sclerosis Disease: Brain: Pons

T2236071Msc 5 slides
EUR 262

Total Protein - Parkinson's Disease: Brain: Frontal Lobe

P1236051Par 1 mg
EUR 542

Total Protein - Parkinson's Disease: Brain: Parietal Lobe

P1236066Par 1 mg
EUR 542

Total Protein - Parkinson's Disease: Brain: Temporal Lobe

P1236078Par 1 mg
EUR 542

Total Protein - Parkinson's Disease: Brain: Occipital Lobe

P1236062Par 1 mg
EUR 542

This model system has been very successful in the case of post-mortem tissue because of their relative accessibility to acute brain slices or culture. The current review usage details synaptosomes in AD research and its potential as a valuable tool in furthering our understanding of the pathogenesis and in designing and testing therapeutic strategies for this disease.